ABSTRACT
Frozen shoulder is a common shoulder concern with a prevalence of 2-5 per cent in the general population that affects the shoulder joint between the ages of 40 and 60, mostly in female subjects, manifesting in progressive loss of glenohumeral movements associated with intense pain.
The pathological process consists of a fibroproliferative tissue fibrosis and an inflammation of the synovial membrane. Although the pathophysiology of this condition has been deeply studied, the mechanisms underpinning remain poorly understood.
Frozen shoulder manifests clinically as shoulder pain with progressive restricted movement, both active and passive, in the absence of trauma, along with normal radiographic scans of the glenohumeral joint.
It classically progresses through 3 overlapping stages of pain (stage 1, lasting 2-9 months), stiffness (stage 2, lasting 4-12 months) and recovery (stage 3, lasting 5-24 months); however, up to day seems that pain-predominant and stiff-predominant phases could be more usefull in treatment modality choice and managing.
The medical management has not been defined with a wide spectrum of operative and nonoperative treatments available. The most widely used treatments are local steroid and/or anesthetic injections, stretching, active and passive mobilization, physiotherapy, hydrodistension, capsular release; hoverver, he goals of the treatment are pain management, shoulder function restoration and improvement in quality of life. Based on the best available evidence it appears that the use of corticosteroid injections plus physiotherapy has been associated with better outcomes above all in terms of early benefit in ER ROM with clinical significance as long as 6 weeks of treatments.
Nevertheless, it remains unclear which parameters influence the prognosis of the pathology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of University of Molise gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funder No fundings were provided for this study
Data Availability
All data produced in the present study are available upon reasonable request to the authors
